

Anticoagulants utilization in Portugal: are there inequalities?

Filipa A. Costa^{1,5}, Inês Teixeira², Sérgio Vilão³ and Sotiris Antoniou^{4,5}

1. Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Caparica, Portugal
2. Centre for Health Evaluation and Research (CEFAR), Associação Nacional das Farmácias (ANF), Lisbon, Portugal
3. Formifarma, Estoril, Portugal
4. Barts Health NHS Trust, UCL School of Pharmacy
5. International Pharmacists for Anticoagulation Care Taskforce

Background

- Anticoagulation (AC) is required in various conditions: DVT Prophylaxis (Orthopedic Surgery), NVAf (to reduce stroke risk), DVT or PE Treatment
- AC may be assured using: heparins, VKAs and NOACs
- Interesting for PNHS: costs increased 0.8% and AC represent the 3rd FT group with greater weight (7.7%; 84 M€; Δ 27.7%)(¹)


Objectives

- This study analyses the utilisation patterns of AC in Portugal, in the outpatient market, considering national, regional and international asymmetries.
- It also analyses the evolution of costs (for the PNHS and for patients) and the costs of treatment per day.

Methods

- Descriptive study considering a 10 year-period (2006 to 2015)
- Outpatient sales data obtained from INFARMED to characterise AC use.
- Data treated annually and disaggregated by the 18 districts of Portugal, considering ATC classification (B01A Antithrombotic Agents) and respective DDDs.⁽¹⁾
- Utilisation indicators used: DDDs, DID (DDDs/1000 inhabitants/day), considering the mean annual resident population in mainland Portugal⁽²⁾ and the ratio of NOACs on the total market of ACs.
- Cost indicators used: total costs, PNHS costs, out-of-pocket (OOP) costs and costs of treatment per day (CTD).


Results: % Ratio of NOACs on total AC market international comparison



Source: adapted from IMS, 2015

% Ratio of NOACs on total AC market in mainland Portugal (PNHS) by district and region, in packages (2015)


Region	Ratio 2015
North	24.8%
Center	40.1%
LVT	43.3%
Alentejo	33.7%
Algarve	46.1%
Mainland Portugal	35.9%






Source: own development, INFARMED data

Year 2006: DID Total PNHS 4,28



Year 2015: DID Total PNHS 17,03




Região	Distrito	2006	2015	Var
North	Braga	5,77	16,32	183%
North	Bragança	3,52	19,81	464%
North	Porto	4,81	15,07	213%
North	Viana do Castelo	7,27	21,20	192%
North	Vila Real	4,77	19,76	314%
Center	Aveiro	4,32	17,79	312%
Center	Castelo Branco	4,29	22,88	433%
Center	Coimbra	3,86	26,51	587%
Center	Guarda	3,48	19,56	462%
Center	Leiria	3,65	17,62	383%
Center	Viseu	3,62	21,69	499%
LVT	Lisboa	3,90	16,02	311%
LVT	Santarém	4,01	17,57	338%
LVT	Setúbal	3,60	14,96	315%
Alentejo	Beja	2,23	11,55	418%
Alentejo	Évora	5,30	20,03	278%
Alentejo	Portalegre	3,21	14,76	360%
Algarve	Faro	3,50	14,12	303%
TOTAL PNHS		4,28	17,03	298%



Results: Costs



Discussion & Conclusion: Potential influence of guidelines on drug use



Thank you for your attention!